26, 19661975 10.1161/01.ATV.0000232525.65682.a2 [DOI] [PubMed] [Google Scholar] Dermietzel R., Krause D., Kremer M., Wang C., Stevenson B
Thus, we hypothesized that GSH depletion enhances the oxidation of key lipogenic factors, rendering them dysfunctional and targeting them for degradation
UPS participates in both pro- and anti-fibrotic processes through the degradation of several TGF-/Smad signaling pathway constituents
ngz DF, Bozkurt DS, Balli U, Avci B, Durmu?lar MC, et al
Disclosures: Madeleine Chang: Nothing to Disclose, Mazen Noureddin: ltimmune, BI, Cytodyn, 89BIO, GSK, Madrigal, Merck, Novo Nor: Terns,Takeda, Zydus., Allergan, Akero, BI, BMS, Gilead, Galectin, Zydus GSK: Terns, Corcept, Takeda, Madrigal, Novartis, Novo Nordisk, Rivus Pharma, Cytodyn, and ChronWell: Stock privately held company 837 NONINVASIVE ASSESSMENT OF STEATOTIC LIVER DISEASE IN INDIVIDUALS WITH CLASS 2 AND CLASS 3 OBESITY Michael Thornton 1 Jang Hwan Cho 1 Idan Steinberg 1 Jing Gao 2 Colby Adamson 2 , 1 ENDRA Life Sciences Inc, 2 Rocky Vista University Background: The current standard of practice in the noninvasive assessment of steatotic liver disease at the point-of-care, is by quantitative Ultrasound (QUS)
151 Triggering ferroptosis using system Xc inhibitors Erastin is a first-generation ferroptosis inducer that directly suppresses system Xc 1